BACKGROUND: Adult intracranial ependymoma is rare, and the role for adjuvant radiotherapy (RT) is not well defined. METHODS: We used the National Cancer Database (NCDB) to select adults (age ≥ 22 years) with grade 2 to 3 intracranial ependymoma status postresection between 2004 and 2015 and treated with adjuvant RT vs observation. Four cohorts were generated: (1) all patients, (2) grade 2 only, (3) grade 2 status post-subtotal resection only, (4) and grade 3 only. The association between adjuvant RT use and overall survival (OS) was assessed using multivariate Cox and propensity score matched analyses. RESULTS: A total of 1787 patients were included in cohort 1, of which 856 patients (48%) received adjuvant RT and 931 (52%) were observed. Approximately two-thirds of tumors were supratentorial and 80% were grade 2. Cohorts 2, 3, and 4 included 1471, 345, and 316 patients, respectively. There was no significant association between adjuvant RT use and OS in multivariate or propensity score matched analysis in any of the cohorts. Older age, male sex, urban location, higher comorbidity score, earlier year of diagnosis, and grade 3 were associated with increased risk of death. CONCLUSIONS: This large NCDB study did not demonstrate a significant association between adjuvant RT use and OS for adults with intracranial ependymoma, including for patients with grade 2 ependymoma status post-subtotal resection. The conflicting results regarding the efficacy of adjuvant RT in this patient population highlight the need for high-quality studies to guide therapy recommendations in adult ependymoma.
BACKGROUND: Adult intracranial ependymoma is rare, and the role for adjuvant radiotherapy (RT) is not well defined. METHODS: We used the National Cancer Database (NCDB) to select adults (age ≥ 22 years) with grade 2 to 3 intracranial ependymoma status postresection between 2004 and 2015 and treated with adjuvant RT vs observation. Four cohorts were generated: (1) all patients, (2) grade 2 only, (3) grade 2 status post-subtotal resection only, (4) and grade 3 only. The association between adjuvant RT use and overall survival (OS) was assessed using multivariate Cox and propensity score matched analyses. RESULTS: A total of 1787 patients were included in cohort 1, of which 856 patients (48%) received adjuvant RT and 931 (52%) were observed. Approximately two-thirds of tumors were supratentorial and 80% were grade 2. Cohorts 2, 3, and 4 included 1471, 345, and 316 patients, respectively. There was no significant association between adjuvant RT use and OS in multivariate or propensity score matched analysis in any of the cohorts. Older age, male sex, urban location, higher comorbidity score, earlier year of diagnosis, and grade 3 were associated with increased risk of death. CONCLUSIONS: This large NCDB study did not demonstrate a significant association between adjuvant RT use and OS for adults with intracranial ependymoma, including for patients with grade 2 ependymoma status post-subtotal resection. The conflicting results regarding the efficacy of adjuvant RT in this patient population highlight the need for high-quality studies to guide therapy recommendations in adult ependymoma.
Authors: E Susan Amirian; Terri S Armstrong; Kenneth D Aldape; Mark R Gilbert; Michael E Scheurer Journal: Neuroepidemiology Date: 2012-07-28 Impact factor: 3.282
Authors: Stephan Dützmann; Bawarjan Schatlo; Alexander Lobrinus; Michael Murek; Maria Wostrack; Carolin Weiss; Karl Schaller; Andreas Raabe; Bernhard Meyer; Roland Goldbrunner; Kea Franz; Volker Seifert; Christian Senft Journal: J Neurooncol Date: 2013-06-29 Impact factor: 4.130
Authors: Benjamin H Kann; Henry S Park; Nataniel H Lester-Coll; Debra N Yeboa; Viviana Benitez; Atif J Khan; Ranjit S Bindra; Asher M Marks; Kenneth B Roberts Journal: JAMA Oncol Date: 2016-12-01 Impact factor: 31.777
Authors: Kristian W Pajtler; Stephen C Mack; Vijay Ramaswamy; Christian A Smith; Hendrik Witt; Amy Smith; Jordan R Hansford; Katja von Hoff; Karen D Wright; Eugene Hwang; Didier Frappaz; Yonehiro Kanemura; Maura Massimino; Cécile Faure-Conter; Piergiorgio Modena; Uri Tabori; Katherine E Warren; Eric C Holland; Koichi Ichimura; Felice Giangaspero; David Castel; Andreas von Deimling; Marcel Kool; Peter B Dirks; Richard G Grundy; Nicholas K Foreman; Amar Gajjar; Andrey Korshunov; Jonathan Finlay; Richard J Gilbertson; David W Ellison; Kenneth D Aldape; Thomas E Merchant; Eric Bouffet; Stefan M Pfister; Michael D Taylor Journal: Acta Neuropathol Date: 2016-11-17 Impact factor: 17.088
Authors: Sunny Shah; Kevin Gates; Chase Mallory; Muni Rubens; Ossama M Maher; Toba N Niazi; Ziad Khatib; Rupesh Kotecha; Minesh P Mehta; Matthew D Hall Journal: Adv Radiat Oncol Date: 2021-03-26
Authors: Roshan S Prabhu; Matthew C Ward; John H Heinzerling; Christopher D Corso; Zachary S Buchwald; Reshika Dhakal; Anthony L Asher; Ashley L Sumrall; Stuart H Burri Journal: Adv Radiat Oncol Date: 2020-10-26